ImageneBio (IMA) vs MiNK Therapeutics (INKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MiNK Therapeutics (INKT) has outperformed ImageneBio (IMA) over the past year, losing 24.1% versus a loss of 44.9%. Over five years, INKT leads with a -96.0% price change compared with -97.9% for IMA. ImageneBio is the larger company by market cap ($48.8 million vs $41.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMA | INKT |
|---|---|---|
| Share price | $3.92 | $8.02 |
| Market cap | $48.83M | $41.17M |
| 1-day change | 0.00% | -6.85% |
| YTD return | -43.19% | -28.07% |
| 1-year return | -44.87% | -24.05% |
| 5-year return | -97.86% | -95.99% |
| EPS (TTM) | $-2.11 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $800.00K | — |
| Revenue growth (YoY) | -77.14% | — |
| Net income (latest FY) | $-45.35M | $-12.49M |
| Operating margin | -6056.38% | — |
| Net margin | -5668.63% | — |
| 52-week high | $7.60 | $16.93 |
| 52-week low | $3.00 | $7.76 |
| Distance from 52-week high | -48.42% | -52.62% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +359.18% | +386.28% |
| Average volume | 15.86K | 15.74K |
| Shares outstanding | 12.46M | 5.13M |
| Employees | 18 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INKT has outperformed IMA by 20.8 percentage points over the past year.
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
IMA vs INKT FAQ
Which is bigger, ImageneBio or MiNK Therapeutics?
ImageneBio (IMA) is larger, with a market capitalization of $48.83M compared with $41.17M for MiNK Therapeutics (INKT).
Which stock has performed better over the past year, IMA or INKT?
INKT returned -24.05% over the past 12 months, compared with -44.87% for IMA (price return, excluding dividends). Past performance does not predict future results.
Are ImageneBio and MiNK Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.